Julie Gay

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 375 citations · Full text

Hematological Malignancy, Medicine, Hematology +6

Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura

Julie Gay, Lionel Galicier, François Provôt et al. · Blood · 2014 · 183 citations · Full text

Early Human Herpesvirus Type 6 Reactivation after Allogeneic Stem Cell Transplantation: A Large-Scale Clinical Study

Rémy Duléry, Julia Salleron, A. Dewilde et al. · Biology of Blood and Marrow Transplantation · 2011 · 115 citations · Full text

Transplantation, Viral Persistence, Quantitative Pcr +13

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

Xavier Leleu, Cyrille Hulin, Jérôme Lambert et al. · Nature Medicine · 2024 · 87 citations · Full text

Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma

Aurore Perrot, Jérôme Lambert, Cyrille Hulin et al. · New England Journal of Medicine · 2025 · 33 citations